

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 8-K

HALOZYME THERAPEUTICS INC

Form 8-K

April 06, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) April 6, 2004

HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Nevada	000-49616	88-0488686
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11588 Sorrento Valley Road, Suite 17
San Diego, California 92121
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (858) 794-8889

Not Applicable
(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.

On April 6, 2004, Halozyme Therapeutics, Inc. ("Halozyme") issued a press release that Robert Engler, M.D., had been named to its Board of Directors. In addition, Ira Lechner, Chairman of the Board, resigned from the Board of Directors and Jonathan Lim, M.D., Halozyme's President and Chief Executive Officer, added the post of Chairman of the Board to his duties. The foregoing is discussed in greater detail in such press release, a copy of which is filed herewith as Exhibit 99.1.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

The following exhibit is filed with this Form 8-K.

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 8-K

Exhibit No. -----	Description -----
99.1	Press Release of April 6, 2004, regarding the appointment of Robert Engler, M.D., to the Board of Directors, the resignation of Ira Lechner from the Board of Directors and the appointment of Jonathan Lim, M.D., as Chairman of the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HALOZYME THERAPEUTICS, INC.

Date: April 6, 2004

By: /s/ Jonathan E. Lim, M.D.

President and Chief Executive Officer